109.44
Precedente Chiudi:
$106.12
Aprire:
$105.41
Volume 24 ore:
754.22K
Relative Volume:
0.63
Capitalizzazione di mercato:
$6.84B
Reddito:
$3.99B
Utile/perdita netta:
$463.16M
Rapporto P/E:
15.41
EPS:
7.1
Flusso di cassa netto:
$1.10B
1 W Prestazione:
+1.23%
1M Prestazione:
+1.27%
6M Prestazione:
-11.13%
1 anno Prestazione:
+2.79%
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Nome
Jazz Pharmaceuticals Plc
Settore
Industria
Telefono
353-1-634-7800
Indirizzo
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Confronta JAZZ con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
JAZZ
Jazz Pharmaceuticals Plc
|
109.44 | 6.84B | 3.99B | 463.16M | 1.10B | 7.10 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-07 | Aggiornamento | UBS | Neutral → Buy |
2025-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2025-02-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2024-12-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2024-06-05 | Iniziato | Goldman | Buy |
2024-01-03 | Iniziato | Robert W. Baird | Outperform |
2023-11-27 | Downgrade | UBS | Buy → Neutral |
2023-09-29 | Iniziato | Raymond James | Mkt Perform |
2023-06-12 | Ripresa | Wells Fargo | Equal Weight |
2022-12-09 | Aggiornamento | Goldman | Neutral → Buy |
2022-06-14 | Iniziato | UBS | Buy |
2022-04-06 | Downgrade | Goldman | Buy → Neutral |
2021-11-19 | Ripresa | Goldman | Buy |
2021-10-07 | Ripresa | Jefferies | Buy |
2021-10-05 | Iniziato | Citigroup | Buy |
2021-09-23 | Iniziato | Needham | Buy |
2021-05-19 | Ripresa | JP Morgan | Overweight |
2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
2021-02-05 | Reiterato | H.C. Wainwright | Buy |
2021-02-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2021-01-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2020-12-16 | Iniziato | UBS | Buy |
2020-11-03 | Reiterato | H.C. Wainwright | Buy |
2020-10-09 | Reiterato | H.C. Wainwright | Buy |
2020-09-14 | Downgrade | Goldman | Neutral → Sell |
2020-09-14 | Ripresa | JP Morgan | Overweight |
2020-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2020-07-28 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
2020-07-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2020-04-06 | Iniziato | Jefferies | Buy |
2020-03-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
2020-01-08 | Iniziato | Goldman | Neutral |
2019-08-21 | Downgrade | Piper Jaffray | Overweight → Neutral |
2019-06-11 | Iniziato | Barclays | Overweight |
2019-03-20 | Iniziato | SunTrust | Buy |
2018-12-14 | Iniziato | Wolfe Research | Peer Perform |
2018-11-08 | Reiterato | B. Riley FBR | Buy |
2018-08-08 | Reiterato | Stifel | Buy |
2018-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2018-03-23 | Reiterato | H.C. Wainwright | Neutral |
2018-03-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
FDA Approvals and Clinical Trials Impacting Narcolepsy - openPR.com
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Autistic Disorder Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Jazz Pharma, Axial Therapeutics, Eli Lilly and Company, Scioto Biosciences - Barchart.com
Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav® - Insider Monkey
Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav®. - Yahoo Finance
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
Jazz Pharmaceuticals (JAZZ) Stock Ratings Reiterated by Needham - GuruFocus
Jazz Pharmaceuticals at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Nigeria
Transcript : Jazz Pharmaceuticals plc Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
Transcript : Jazz Pharmaceuticals plcSpecial Call - MarketScreener
Jazz Pharmaceuticals Says Zepzelca-Tecentriq Combination Gets FDA Priority Review for Lung Cancer Treatment - marketscreener.com
FDA Fast-Tracks Jazz Pharmaceuticals' Lung Cancer Drug Application - GuruFocus
Jazz Pharma stock gains on FDA review for lung cancer therapy - Seeking Alpha
Jazz Pharmaceuticals (JAZZ) Awaits FDA Decision on Lung Cancer Treatment | JAZZ Stock News - GuruFocus
FDA Fast-Tracks Revolutionary Lung Cancer Drug That Cuts Disease Progression Risk by 46% - Stock Titan
Jazz Pharmaceuticals Says Narcolepsy Drug Meets Primary Endpoint in Phase 4 Trial - marketscreener.com
Parallel Advisors LLC Acquires 119 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World
Jazz Pharmaceuticals (JAZZ) Reveals New Findings on Xywav at SLE - GuruFocus
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcas - GuruFocus
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025 - PR Newswire
Jazz Pharmaceuticals' Xywav Achieves 4.1 mmHg Blood Pressure Reduction in Groundbreaking Phase 4 Trial - Stock Titan
Transcript : Jazz Pharmaceuticals plc Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 09 - MarketScreener
Jazz Pharmaceuticals misses estimates, slashes guidance on litigation costs By Investing.com - Investing.com Nigeria
Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report? - Yahoo Finance
May 2026 Options Now Available For Jazz Pharmaceuticals - Nasdaq
Needham Says Promising Data Underscore Growth Potential for Jazz Pharma (JAZZ) - MSN
Insider Sell: Bruce Cozadd Sells Shares of Jazz Pharmaceuticals PLC - GuruFocus
Jazz Pharmaceuticals plc (JAZZ)’s Zepzelca Combo Boosts Survival in ES-SCLC - MSN
Psychedelic Drugs Market 2025 | Growth Trends, Mental Health - openPR.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) Given “Buy” Rating at Needham & Company LLC - Defense World
Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer StudyJazz Pharmaceuticals (NASDAQ:JAZZ) - Benzinga
UBS maintains buy rating on Jazz Pharmaceuticals stock after positive trial data - Investing.com Nigeria
Jazz Pharmaceuticals succeeds in late-stage study of lung cancer treatment - MSN
The Analyst Verdict: Jazz Pharmaceuticals In The Eyes Of 11 Experts - Benzinga
Jazz Pharmaceuticals (JAZZ) Maintains Buy Rating with $202 Price Target | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals reports promising Phase 2 trial results for Ziihera By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals (JAZZ) Reports Positive Results for Zepzelc - GuruFocus
Jazz Pharmaceuticals (JAZZ) Reveals Promising Phase 3 Trial Resu - GuruFocus
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination - marketscreener.com
Jazz Pharmaceuticals (JAZZ) Reveals Promising Phase 3 Trial Results for Zepzelca | JAZZ Stock News - GuruFocus
Zepzelca combo extends survival in lung cancer study - Investing.com
Phase 3 Trial: Zepzelca Combo Cuts Lung Cancer Progression Risk by 46% | JAZZ Stock News - Stock Titan
Jazz Pharmaceuticals (JAZZ) Reports Promising Long-term Data for Ziihera | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals Says Ziihera Achieves Over 3 Years Median Overall Survival in Gastroesophageal Cancer - marketscreener.com
Jazz Pharmaceuticals reports promising Phase 2 trial results for Ziihera - Investing.com
Jazz Pharmaceuticals (JAZZ) Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera in mGEA - StreetInsider
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025 - PR Newswire
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - GlobeNewswire Inc.
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Como - GuruFocus
Jazz Pharmaceuticals Reveals 19 New Xywav Studies for Sleep Disorders at SLEEP 2025 | JAZZ Stock News - Stock Titan
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025 - PR Newswire
Jazz Pharmaceuticals Plc Azioni (JAZZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Jazz Pharmaceuticals Plc Azioni (JAZZ) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
COZADD BRUCE C | Chairman & CEO |
Jun 02 '25 |
Sale |
107.90 |
500 |
53,950 |
438,473 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):